Celularity Inc

Celularity Inc. (“Celularity”) will be unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the three and six months ended June 30, 2026 (the “June 2026 Form 10-Q”) with the Securities and Exchange Commission (“SEC”) within the prescribed time period. Constraints in Celularity’s liquidity position and financial accounting staffing levels have caused delays in the financial close and reporting process and the preparation of the consolidated financial statements. Celularity is working diligently and plans to file the June 2026 Form 10-Q as soon as practicable

Celularity Inc. (“Celularity”) will be unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the three months ended March 31, 2026 (the “March 2026 Form 10-Q”) with the Securities and Exchange Commission (“SEC”) within the prescribed time period. Constraints in Celularity’s liquidity position and financial accounting staffing levels caused a delay in the financial close and reporting process and preparation of the consolidated financial statements. Celularity is working diligently and plans to file the March 2026 Form 10-Q as soon as practicable

Celularity Inc. (“Celularity”) will be unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the year ended December 31, 2025 (the “2025 Form 10-K”) with the Securities and Exchange Commission (“SEC”) within the prescribed time period. Constraints in Celularity’s liquidity position and financial accounting staffing levels caused a delay in the financial close and reporting process and preparation of the consolidated financial statements. Celularity is working diligently and plans to file the 2025 Form 10-K as soon as practicable

Celularity Inc. (“Celularity”) will be unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the year ended December 31, 2024 (the “2024 Form 10-K”) with the Securities and Exchange Commission (“SEC”) within the prescribed time period. Constraints in Celularity’s liquidity position and financial accounting staffing levels caused a delay in the financial close and reporting process and preparation of the consolidated financial statements. Celularity is working diligently and plans to file the 2024 Form 10-K as soon as practicable

Celularity Inc. (the “Company”) will be unable to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the “Q3 2024 Form 10-Q”) with the Securities and Exchange Commission (“SEC”) within the prescribed time period. Constraints in the Company’s liquidity position and financial accounting staffing levels caused a delay in the financial close and reporting process and preparation of the consolidated financial statements. Additionally, on August 2, 2024, the Company engaged a new independent registered public accounting firm to audit its consolidated financial statements for the year ending December 31, 2024, which resulted in further delays. Despite working diligently in an effort to timely file the Q3 2024 Form 10-Q, the Company has been unable to complete all work necessary to timely file the Q3 2024 Form 10-Q. As of the date of this Notification of Late Filing (Form 12b-25), the Company has not yet completed the preparation of the financial statements for the quarter ended September 30, 2024. The Company is working diligently and plans to file the Q3 2024 Form 10-Q with the SEC as soon as practicable

Celularity Inc. (the “Company”) will be unable to file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (the “Q2 2024 Form 10-Q”) with the Securities and Exchange Commission (“SEC”) within the prescribed time period. Constraints in Celularity’s liquidity position and financial accounting staffing levels caused a delay in the financial close and reporting process and preparation of the consolidated financial statements. The Company also recently changed audit firms. Despite working diligently in an effort to timely file the Q2 2024 Form 10-Q, the Company has been unable to complete all work necessary to timely file the Q2 2024 Form 10-Q. As of the date of this Notification of Late Filing (Form 12b-25), the Company has not yet completed the preparation of the financial statements for the quarter ended June 30, 2024. The Company is working diligently and plans to file the Q2 2024 Form 10-Q with the SEC as soon as practicable

Celularity Inc. (the “Company”) will be unable to file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (the “Q1 2024 Form 10-Q”) with the Securities and Exchange Commission (“SEC”) within the prescribed time period. Constraints in Celularity’s liquidity position and financial accounting staffing levels caused a delay in the financial close and reporting process and preparation of the consolidated financial statements. Despite working diligently in an effort to timely file the Q1 2024 Form 10-Q, the Company has been unable to complete all work necessary to timely file the Q1 2024 Form 10-Q. As of the date of this Notification of Late Filing (Form 12b-25), the Company has not yet completed the preparation of the financial statements for the quarter ended March 31, 2024. The Company is working diligently and plans to file the Q1 2024 Form 10-Q with the SEC as soon as practicable

Celularity Inc. (“Celularity”) will be unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Form 10-K”) with the Securities and Exchange Commission (“SEC”) within the prescribed time period. Constraints in Celularity’s liquidity position and financial accounting staffing levels caused a delay in the financial close and reporting process and preparation of the consolidated financial statements. Despite working diligently in an effort to timely file its 2023 Form 10-K, Celularity has been unable to complete all work necessary to timely file its 2023 Form 10-K. As of the date of this Notification of Late Filing (Form 12b-25), Celularity has not yet completed the preparation of the financial statements for the year ending December 31, 2023. Celularity is working diligently and plans to file the 2023 Form 10-K as soon as practicable

Celularity Inc. (the “Company”) was unable to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the “Q3 Form 10-Q”) with the Securities and Exchange Commission (“SEC”) within the prescribed time period. Despite working diligently in an effort to timely file its Q3 Form 10-Q, the Company has been unable to complete all work necessary to timely file its Q3 Form 10-Q. As of the date of this Notification of Late Filing (Form 12b-25), the Company has not yet completed the preparation of the financial statements, including its goodwill impairment testing for the quarter ended September 30, 2023. Although not yet complete, the Company anticipates a material goodwill impairment charge on its Cell Therapy reporting unit between $26 and $83 million. The expected impairment charge with reduce the Company’s assets and will contribute towards the Company incurring a net loss for the quarter ended September 30, 2023

Celularity Inc. (the “Company”) was unable to file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 (the “Q1 Form 10-Q”) with the Securities and Exchange Commission (“SEC”) within the prescribed time period. Despite working diligently in an effort to timely file its Q1 Form 10-Q, the Company has been unable to complete all work necessary to timely file its Q1 Form 10-Q. As of the date of this Notification of Late Filing (Form 12b-25), the Company has not yet completed its goodwill impairment testing for the quarter ended March 31, 2023. Although not yet complete, the Company anticipates a material goodwill impairment charge on its Cell Therapy reporting unit between $25 and $35 million. The Company expects to file its Q1 Form 10-Q with the SEC as soon as practicable, and no later than the fifth calendar day following the prescribed due date, in accordance with Rule 12b-25

Celularity Inc. (the “Company”) was unable to file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 (the “Q2 Form 10-Q”) with the Securities and Exchange Commission (“SEC”) within the prescribed time period. Despite working diligently in an effort to timely file its Q2 Form 10-Q, the Company has been unable to complete all work necessary to timely file its Q2 Form 10-Q. The Company expects to file its Q2 Form 10-Q with the SEC as soon as practicable, and no later than the fifth calendar day following the prescribed due date, in accordance with Rule 12b-25

GX Acquisition Corp. (the “ Company ”) has determined that it is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2021 (the “Q1 2021 Form 10-Q”) by the prescribed filing date due to the reasons described below. The Company is working diligently to complete the Q1 2021 Form 10-Q as soon as possible; however, given the scope of the process for evaluating the impact on the Company’s financial statements of the Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (the “SEC Statement”) issued by the staff of the Securities and Exchange Commission on April 12, 2021 and ASC 815-40, the Company is unable to complete and file the Q1 2021 Form 10-Q by the required due date of May 17, 2021 without unreasonable effort and expense. The Company does, however, expect to file such report within five calendar days thereof. After consideration of the guidance in the SEC Statement, the Company concluded that its outstanding warrants should be accounted for as a liability and measured at fair value with changes in fair value each period reported in the Company’s statement of operations. The Company completed its final analysis of this change and the impact is expected to be material to the Company’s previously filed financial statements and also anticipates that significant changes in its results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in its Q1 2021 Form 10-Q